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Abstract
BACKGROUND: Smoking rates in methadone-maintained patients are almost three times higher than
in the general population and remain elevated and stable. Due to the various negative health effects of
smoking, nicotine dependence contributes to the high mortality in this patient group. The purpose of the
current study was to investigate Swiss methadone and buprenorphine-maintained patients' willingness to
stop smoking and to clarify further smoking cessation procedures. METHODS: Substance abuse history,
nicotine dependence, and readiness to stop smoking were assessed in a sample of 103 opiate-dependent
patients in the metropolitan area of Zurich, Switzerland. Patients were asked to document their smoking
patterns and readiness to quit. RESULTS: Only a small number of patients were willing to quit smoking
cigarettes (10.7%) and, even though bupropione or nicotine replacement therapy was included in the
fixed daily treatment care, only one patient received nicotine replacement therapy for smoking
cessation. A diagnosis of depression in patients' clinical records was associated with readiness to stop
smoking. No significant associations were found between readiness to quit smoking and age, methadone
treatment characteristics, and presence of co-dependencies. CONCLUSION: The current prescription
level of best medicine for nicotine dependence in Swiss methadone and buprenorphine-maintained
patients is far from adequate. Possible explanations and treatment-relevant implications are discussed.
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Abstract
Background: Smoking rates in methadone-maintained patients are almost three times higher than
in the general population and remain elevated and stable. Due to the various negative health effects
of smoking, nicotine dependence contributes to the high mortality in this patient group. The
purpose of the current study was to investigate Swiss methadone and buprenorphine-maintained
patients' willingness to stop smoking and to clarify further smoking cessation procedures.
Methods: Substance abuse history, nicotine dependence, and readiness to stop smoking were
assessed in a sample of 103 opiate-dependent patients in the metropolitan area of Zurich,
Switzerland. Patients were asked to document their smoking patterns and readiness to quit.
Results: Only a small number of patients were willing to quit smoking cigarettes (10.7%) and, even
though bupropione or nicotine replacement therapy was included in the fixed daily treatment care,
only one patient received nicotine replacement therapy for smoking cessation. A diagnosis of
depression in patients' clinical records was associated with readiness to stop smoking. No
significant associations were found between readiness to quit smoking and age, methadone
treatment characteristics, and presence of co-dependencies.
Conclusion: The current prescription level of best medicine for nicotine dependence in Swiss
methadone and buprenorphine-maintained patients is far from adequate. Possible explanations and
treatment-relevant implications are discussed.
Background
Growing public awareness of the public health issues of
cigarette smoking has led to the implementation of smok-
ing prevention programs, age limits for tobacco sales, and
smoking bans in public spaces in many western Europe
countries. These measures have brought about substantial
improvements, with overall smoking rates among adults
declining to 20–40% in various countries [1,2]. In Swit-
zerland rates vary between 30 and 40% [3]. However,
smoking rates for patients with a substance use disorder
remain high and stable [4]. Numerous studies suggest that
smoking rates are almost three times higher in opiate-
dependent persons in methadone treatment programs as
compared to the general population [5-7].
Published: 18 March 2008
Harm Reduction Journal 2008, 5:10 doi:10.1186/1477-7517-5-10
Received: 1 October 2007
Accepted: 18 March 2008
This article is available from: http://www.harmreductionjournal.com/content/5/1/10
© 2008 Wapf et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 7
(page number not for citation purposes)
Harm Reduction Journal 2008, 5:10 http://www.harmreductionjournal.com/content/5/1/10For unknown reasons, the majority of patients receiving
methadone maintenance treatment are cigarette smokers.
Due to the various negative health effects of smoking, nic-
otine dependence contributes to the high mortality in this
patient group. Nevertheless, many psychiatrists and other
mental health professionals are often reluctant to address
the problem of nicotine abuse in their patients suffering
from substance use disorders. Olsen et al. [8] reported
that, although addiction counseling is required in metha-
done programs, nicotine dependence rarely receives atten-
tion.
The reluctance of care providers has been partially attrib-
uted to a fear that the stress of smoking cessation would
lead to a relapse into the abuse of other substances [9].
Despite preliminary evidence that smoking cessation
counseling can be provided without necessarily leading to
a relapse with other substances [10], some therapists
believe that smoking serves as an effective coping tool to
deal with cravings for other substances such as heroin and
cocaine [11]. There is some support for an association
between cigarette smoking and methadone dose in that
methadone patients who exhibited higher smoking rates
are significantly more likely to report problems of not
feeling "held" by their methadone dose and to experience
a higher level of anxiety [12]. More adequate methadone
dosing would probably reduce such effects.
On the other hand, the therapists' reluctance may reflect
limited motivation on the patients' part. Hayaki et al. [13]
demonstrated that many smokers underestimate their
personal susceptibility to the negative health effects
brought about by smoking (e.g., increased risk for onco-
logical and cardiovascular disease). As stated by Kolly et
al. [14], a number of patients and treatment professionals
believe that smoking is a minor issue compared to illegal
drug consumption. Other studies, however, have demon-
strated that many patients are interested in quitting smok-
ing [7,15-17] and that smoking cessation does not
jeopardize progresses made in treatment [18]. As deline-
ated by Baran-Furga et al. [19], initiation of methadone
maintenance treatment can also be associated with posi-
tive changes in smoking behavior. But on the other hand,
studies on smoking cessation programs in methadone
maintenance treatment have not been very promising
[20] and the large majority of these patients in smoking
cessation programs have been reported to relapse at fol-
low-up even when nicotine replacement therapy has been
combined with otherwise efficacious therapy approaches
such as relapse prevention or contingency management
[21].
One frequently applied concept when investigating
whether individuals are likely to stop smoking is the
stages of change paradigm [22]. To our knowledge, there
are currently only two publications, both from the U. S.,
considering readiness to quit smoking in methadone-
maintained patients. A study by Shadel et al. [23] of smok-
ers enrolled in a smoking cessation research protocol
revealed that, among various factors (demographics,
methadone dose, numbers of smoking quits, age of first
regular smoking, mood and depression), only the number
of cigarettes smoked per day and high scores on smoking
expectancies were associated with motivation to quit
smoking as assessed by a 10-point readiness to change
scale. The first study [24] investigating readiness to stop
smoking with the Smoking Stages of Change Algorithm
[25] in methadone-maintained patients found that prior
use of smoking cessation pharmacotherapy and lower
methadone doses were associated with being in the prep-
aration stage (patients reporting an intention to stop
smoking within the following 30 days). The proportion of
methadone patients being in different stages of change in
this study [24] was similar to that observed in the general
population [26].
The purpose of the current study was therefore to investi-
gate (1) Swiss methadone and buprenorphine-main-
tained patients' willingness to stop smoking cigarettes, (2)
to investigate their previous pharmacotherapy as regards
smoking cessation, and (3) to determine whether these
factors are associated with demographics, co-dependen-
cies, methadone substitution doses and duration, and co-
occurring mental health diagnoses.
Methods
This was a cross-sectional study designed to compare
patients' willingness to stop smoking cigarettes and possi-
ble associations with demographic variables as well as co-
morbid and co-dependence characteristics.
Study subjects
The study sample was recruited from all opiate-dependent
outpatients in methadone or buprenorphine mainte-
nance therapy at the specialized outpatient facility of the
Psychiatric University Clinic in Zurich, Switzerland (n =
233). Bupropione or nicotine replacement therapy was
included in the fixed daily treatment care and available for
the physicians and the maintenance personnel along with
the other pharmacological inventory in the medicine cup-
board behind the methadone maintenance counter. A
physician offered the opportunity to participate prior to
or after a consultation (and/or receiving their regular
methadone/buprenorphine dose). Of those approached,
105 patients participated in the study and two patients
were excluded according to the studies' exclusion criteria
(acute cocaine, amphetamine, heroin, cannabis, alcohol,
sedatives and/or hallucinogen intoxication or acute psy-
chosis) at the time of recruitment. Finally, 103 patients
fully completed the study questionnaire.Page 2 of 7
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be handled confidentially and they were informed of their
right to withdraw from the study at any time without any
negative consequences regarding their treatment. In par-
ticular, patients were reassured that their access to medical
care would not be affected in any way by their choice to
participate or not. By signing the consent form, patients
stated their understanding of the study procedure and
their willingness to participate. Shortly afterwards,
patients could complete the study questionnaire anony-
mously and independently in the waiting room and were
paid Euro 2.50 (CHF 5) for their inconvenience. The study
protocol was approved by the ethics committee at the
University of Zurich and by the established community
based ethics committee.
Measures
Willingness to stop smoking cigarettes was assessed using
the Stages of Change Algorithm [25]. Although the stages
of change concept has been criticized [27], there is a wide
consensus that people who state that they are willing to
stop smoking are more likely to actually quit than those
who do not, and that evidence-based smoking cessation
treatments are substantially more promising for moti-
vated smokers than for unmotivated ones [28,29].
According to the Stages of Change Algorithm, smokers
who seriously considered stopping within the next six
months were classed as being in the "contemplation"
stage, those who did not consider quitting were defined as
"pre-contemplators". Patients who intended to stop
smoking within the following 30 days were considered to
be in the "preparation" stage (provided that they had
undergone more than one previous attempt to quit smok-
ing). Those who did not report such attempts, but
intended to stop within the next month, were also consid-
ered "contemplators". Not smoking for less than six
months and not smoking for more than six-months was
graded as stage of action or maintenance, respectively. The
Fagerstrom Test of Nicotine Dependence FTND [30], a
widely used paper-and-pencil test, was used to measure
the severity of nicotine dependence. Nicotine dependence
was categorized as follows: FTND scores from 0 to 2: low
dependence, 3 to 5: moderate dependence, 6 to 7: high
dependence, and 8 to 10: very high dependence. Further-
more, patients were asked to imagine whom they would
approach (six possible answers) if they wished to reduce
or stop their cigarette consumption. Data on patients'
demographics, mental health and other diagnoses, sub-
stance dependencies and previous nicotine replacement
and/or bupropion therapy were obtained from their med-
ical records.
Data management and analyses
Data were recorded using a relational database. All survey
results were coded and recorded anonymously. Data were
analyzed with the statistical software package SPSS, ver-
sion 11.
To explore associations between readiness to stop smok-
ing and the above mentioned variables, non-parametric
tests (Kruskal-Wallis Chi-Square) were chosen, due to the
skewed nature of the values' distribution. To adjust for
effects of potential confounders, a mixed general linear/
logistic regression model was applied. P values < 0.05
were considered statistically significant. Power calculation
revealed that a sample of 100 ± 5 subjects would be
needed to test each variable with a power of >60%.
Results
Sample characteristics
Males comprised 75% of the sample. Patients' age ranged
between 18 and 50 with a mean of 33.8 (± 7.4) years. The
majority was treated with methadone (74.8% in fluid
form, 10.7% in form of suppositories, 1.0% in form of
pills), and the remaining patients received buprenorphine
(13.6%). The mean number of enrollments in mainte-
nance treatment (including the current one) was 3.1 (±
4.8) with a mean duration of 60.0 (± 42.7) months. The
mean number of opiate withdrawal attempts was 3.9 (±
3.0).
Stages of change
The majority of respondents (71.9%) were in the pre-con-
templation stage. There were 17.5% in the contemplation
and 2.9% in the preparation stage (see table 1). Only a
small group of study participants was in the maintenance
or action stage (3.9% each). To reduce effects of skewness
and to facilitate the use of statistical tests, the values of
Stages of Change variables were dichotomized post hoc as
follows: patients in pre-contemplation and contempla-
tion stages were compared with those in preparation,
action and maintenance stages.
In a series of exact Kruskal-Wallis Chi-Square tests, a sig-
nificant positive association with readiness to stop smok-
ing was found with female gender (not ready: 21.7%,
ready: 45.5%; Chi-Square = 4.369, df = 1, p < 0.05) and
with the presence of depression (not ready: 30.4%, ready:
63.7%; Chi-Square = 5.783, df = 1, p < 0.05). The logistic
regression confirmed the association with depression (OR
= 5.78, 95 CI = 1.32–25.29, p < 0.05) but not with female
gender (OR = 1.9, 95% CI = 0.47–7.92, n.s.).
No differences were found between the preparation-
action-maintenance group and the pre-contemplation/
contemplation group (see table 2) regarding mean age
(not ready: 33.9 (± 7.6), ready: 32.5 (± 5.9); Chi-Square =
0.190, df = 1, n.s.) and the number of participants who
reported co-dependence of cannabis (not ready: 21.7%,
ready: 18.2%; Chi-Square = 0.855, df = 1, n.s.), cocainePage 3 of 7
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= 1, n.s.), sedatives (not ready: 39.1%, ready: 18.2%; Chi-
Square = 1.637, df = 1, n.s.) or alcohol (not ready: 26.1%,
ready: 18.2%; Chi-Square = 1.395, df = 1, n.s.). Likewise,
there were no significant differences between those two
groups regarding methadone dose (not ready: 125.4 (±
84.0), ready: 77.1 (± 34.0); Chi-Square = 1.964, df = 1,
n.s.), age of first regular use of heroin (not ready: 19.7 (±
6.0), ready: 21.4 (± 7.0); Chi-Square = 0.260, df = 1, n.s.),
and history of substitution therapy (number of previous
substitutions (not ready: 3.1 (± 5.0), ready: 2.8 (± 1.1);
Chi-Square = 0.816, df = 1, n.s.) and total duration of sub-
stitution (not ready: 59.3 (± 41.5), ready: 71.0 (± 58.3);
Chi-Square = 0.131, df = 1, n.s.)). Furthermore, the mean
number of opiate withdrawal attempts did not differ sig-
nificantly between groups (not ready: 3.7 (± 2.6), ready:
5.7 (± 4.5); Chi-Square = 1.141, df = 1, n.s.).
Thirty-six percent of the patients stated that they would
approach their case-manager (who was a psychologist, a
physician, a social worker, or a nurse) if they wanted to
reduce or stop their cigarette consumption, 19.5%
declared that they would try to reduce smoking on their
own, 13.5% did not know who they would contact,
11.0% would contact a physician from the clinic, 8.5% a
specialized facility outside the clinic, and 13.8% would try
to get help from various other sources.
Nicotine dependence
The average duration of cigarette smoking was 19.6 (±
7.3) years. Almost all respondents were current smokers,
with a mean FTND score of 5.3 (± 2.1) which reflects
moderate dependence. Seventeen percent of subjects were
classed as having a low, 30.1% a moderate, 40.8% a
strong, and 15.5% a very strong level of dependence. Only
9.7% of participants were former smokers (see table 1).
Even though never having smoked was not an exclusion
Table 2: Kruskal-Wallis Chi-Squares for the dichotomized stages 
of change groups indicating readiness to stop cigarette smoking
Not ready Ready Chi-Square
Number of patients 92 11
% female 21.7 45.5 4.369*
Age 33.9; 7.6 32.5; 5.9 0.190
Cigarette Smoking
Age of smoking onset 14.2; 3.7 14.6; 2.7 2.419
Years of smoking 19.8; 7.4 17.8; 6.4 0.585
Number of cigarettes/day 15.5; 8.1 16.0; 7.0 0.008
FTND score 5.3; 2.1 6.5; 2.0 2.171
% nicotine replacement 1.1 0.0 -
Opiate and Maintenance 
History
Age at heroin onset 19.7; 6.0 21.4; 7.0 0.260
Number of opiate substitution 
enrollments
3.1; 5.0 2.8; 1.1 0.816
Total months of opiate 
substitution treatment
59.3; 41.5 71.0; 58.3 0.131
% substituted with methadone 84.8 72.8
Current methadone dose 125.4; 84.0 77.1; 34.0 1.964
% ever had an opiate 
withdrawal attempt
70.6 72.7 0.282
Total number of opiate 
withdrawal attempts
3.7; 2.6 5.7; 4.5 1.141
Co-dependence
% alcohol dependence 26.1 18.2 1.395
% cannabis dependence 21.7 18.2 0.855
% sedative dependence 39.1 18.2 1.637
% cocaine dependence 38.0 45.5 0.458
Number of co-dependencies 
other than nicotine
1.3; 0.9 1.0; 0.5 0.922
Dual Diagnoses
% depression 30.4 63.7 5.783*
% adult ADHD 3.3 0.0 -
% schizophreniform disorder 4.3 9.1 -
* p < 0.05
Table 1: Sample characteristics and smoking variables in opiate-
dependent patients in maintenance treatment (n = 103)





Treated with buprenorphine 14 13.6
Treated with methadone, out of them: 89 86
- in fluid form 77 86.5
- in form of suppositoria 11 12.4
- in form of tablettes 1 1.1
Stages of change
- precontemplation stage 74 71.9
- contemplation stage 18 17.5
- preparation stage 3 2.9
- maintenance stage 4 3.9




Never smokers - - -
Number of cigarettes smoked per day, pcs
- 0–10 16 15.5
- 11–20 36 35
- 21–30 38 37
- >30 10 10
FTND score
- 0–2 (low) 17
- 3–5 (moderate) 28
- 6–7 (strong) 40
- 8–10 (very strong). 15Page 4 of 7
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had never smoked. Only one patient had received nico-
tine replacement. Bupropion had never been prescribed to
any patient prior to the study assessment.
Measures of co-dependence
Four out of five patients (78.6%) suffered from co-
dependencies (other than nicotine and opiates) with only
2.9% of participants reporting a sole opiate dependence.
Nearly every fifth respondent (18.4%) had one co-
dependence, and every third individual had three and
more co-dependencies (37.9%).
Cocaine was the third most commonly used drug after
opiates and tobacco (62%), followed by cannabis
(36.9%), alcohol (19.4%), sedatives (17.5%), and hallu-
cinogens (1.0%).
Dual diagnoses
Adult ADHD was diagnosed in 3.9% of subjects and
36.9% met diagnostic criteria for depression (1.9%
organic depressive disorder; 4.9% cocaine-induced
depression; 1.9% schizoaffective disorder; 4.9% depres-
sive disorder, current mild depressive episode; 4.9% mod-
erate depressive symptoms; 12.6% recurrent depressive
episodes; 0.9% cyclothymia; 1.9% dysthymia; 2.9% anxi-
ety and depressive reaction, mixed). A schizophreniform
disorder was found in 4.9% of all patients.
Discussion
Overall, the investigated sample reflected the demo-
graphic attributes of the total patient population. There
were three times more males than females, which is con-
sistent with previously reported gender compositions for
similar populations in Europe [31] and in the United
States [32].
Smoking variables
Frequency of smoking was also consistent with the known
rates in comparable populations [15,23]. In general, the
opiate-dependent outpatients in the current study had
smoked a large number of cigarettes over many years.
Their nicotine dependence was substantial (as many as
57% of patients were scored as having strong or very
strong dependence in the FTND-test). Most study subjects
(73%) were not willing to stop smoking. This distribution
is similar to other European samples in the general popu-
lation of smokers, for instance, to the results of Etter et al.
[33] in Geneva. However, the results differ from those in
American surveys where these distributions were typically
40% (stage of precontemplation), 40% (contemplation),
and 20% (preparation) in the general population of
smokers [25,26,34] and 43% (contemplation) and 22%
(preparation stage) in methadone-maintained patients
[24]. One obvious explanation for the difference between
the distribution in the study by Nahvi et al. [24] is that vir-
tually none of our patients were ever previously treated
with prescription medication for smoking cessation. By
contrast, half of the patients in the study by Nahvi et al.
[24] were previously treated this way. Other possible
explanations might be that the physicians in Nahvi et al's
[24] study worried more about possible consequences of
smoking tobacco in their patients or had different treat-
ment relevant beliefs than the physicians in our study.
Such explanations could be investigated in further studies.
Moreover, it is unclear if the patients in the Nahvi et al.
[24] study were more concerned about the impact of their
cigarette smoking and were therefore more motivated to
quit smoking. It needs to be clarified whether patients on
steady methadone doses truly care less than the general
population about possible health consequences and if
this could represent one reason for their reduced motiva-
tion to quit.
Co-dependence and comorbidity
As observed by a number of authors, nicotine dependence
can be influenced by comorbid conditions. For instance,
active alcohol abusers are reported to be 60% less likely to
stop smoking than alcohol abstainers [35], and depressed
nicotine and alcohol dependent patients are reported to
be less likely to quit smoking than non-depressed patients
[9]. Nevertheless, there were no significant associations
found in the present sample between alcohol dependence
and willingness to stop smoking.
Among all factors examined, a significant association was
only found with a diagnosis of depression. This result is
consistent with other studies that have found a significant
association between depression and readiness to stop
smoking in general psychiatric samples [36]. Another
study, however, found no such relationship in psychiatric
patients [37]. Since rates of lifetime affective disorders are
high in opiate-dependent populations (e.g. Nunes [38]:
16–75%), it is important to screen patients as they may
show an increased willingness for smoking cessation and
therefore be open to intervention opportunities.
Study limitations
The study design was cross-sectional and correlational
and may therefore suffer from several limitations and
caveats common in this type of research. These include
possible sampling biases and effects of confounding vari-
ables that were unaccounted for. Moreover, recall biases
concerning the dependence and treatment histories may
also have affected results of self-reported treatment dura-
tion and frequency. Last but not least, the generalizability
of our findings in Zurich to populations in other regions
and countries remains unclear.Page 5 of 7
(page number not for citation purposes)
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Willingness to cease smoking was only marginally preva-
lent in this representative sample of Swiss methadone and
buprenorphine-maintained patients. With so much focus
on the reduction of illicit drug use, relatively little atten-
tion has been given to nicotine addiction in this popula-
tion. Therefore, it is important to investigate why there
exists such a widespread complacency in patients but also
in physicians and other treatment personnel. Therefore,
we suggest that health professionals be required to
actively offer their patients more pharmacologically-based
smoking cessation treatments to facilitate quitting and to
alleviate possible adverse effects that often occurring dur-
ing smoking cessation. Most patients stated that they
would approach their direct case-managers if they were
contemplating quitting smoking and thus, case-managers
may pose the most relevant contact persons who could
propose a smoking cessation attempt. The development
of more adequate and tailored motivation-enhancing,
psycho-social and/or psychotherapeutic interventions for
nicotine dependent patients in maintenance treatment
could clarify whether current interventions are specific
enough and if there is greater potential for smoking cessa-
tion than that which is currently achieved in these
patients.
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